Bliss GVS Pharma Limited (506197) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Bliss GVS Pharma Limited ₹105, price ₹684, upside -84.7%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bliss GVS Pharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹65.30 – ₹737.60 · fair‑value band ₹59.83 – ₹167.11 · the ₹684.20 price screens above the ₹104.64 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India.
Show more
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, the company offers therapeutic products consisting of anti-bacterial, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. It also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
Stock analysis
Bliss GVS Pharma Limited (506197) currently trades at ₹684.20, while our model-based Fair Value estimate is ₹104.64, 84.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹159.15 per share, and 0 of the 26 models we run sit above the ₹684.20 price.
Bear case: the Growth DCF group reads lowest at ₹31.15, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹59.83 (bear) to ₹167.11 (bull), the price of ₹684.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bliss GVS Pharma Limited reported revenue of ₹8.1B in FY2025 versus ₹5.8B in FY2021, a compound +8.8%/yr. Reported net income was ₹843M in FY2025, compounding +5.3%/yr from FY2021.
Key figures
Market cap ₹18.0B (≈ $187M) · P/E ratio 24.6 · P/S ratio 2.56 · EPS (TTM) ₹6.63 · Dividend yield 0.3% · Net margin 10.4% · Return on equity 9.2% · Return on assets (EBIT) 6.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 436% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −85%, 506197 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹5.56 to ₹179.80). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹59.83Fair Value ₹104.64Bull ₹167.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹6.13 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2020 (pandemic). Over 10 years: +7.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.2%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 12%
Compare Bliss GVS Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)Health Care · 2315 stocks
Beats the sector median on 7/13 measures
A mixed picture versus its sector peers.
Valuation
Quality Score57 · Above median
Fair Value upside−76.2% · Bottom 25%
Profitability
Return on equity (TTM)9.2% · Above median
Return on assets5.2% · Above median
Net margin (TTM)12.6% · Above median
Operating margin (TTM)15.6% · Above median
Growth and dividend
Revenue growth−27.9% · Bottom 25%
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bliss GVS Pharma Limited (506197) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹104.64 versus a price of ₹684.20, about −85% upside (overvalued).
What is the fair value of 506197?
Our model-based fair value for Bliss GVS Pharma Limited is ₹104.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹684.20.
What is the quality score of 506197?
Bliss GVS Pharma Limited has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bliss GVS Pharma Limited (506197)?
Our model-based price target is the fair value of ₹104.64 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹59.83, optimistic scenario ₹167.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Bliss GVS Pharma Limited stock forecast for 2026?
Our models put fair value at ₹104.64, about −85% upside versus a price of ₹684.20 (overvalued). Cautious scenario ₹59.83, optimistic scenario ₹167.11. The calculation is refreshed regularly with new filings.
What is the revenue of Bliss GVS Pharma Limited (506197)?
Bliss GVS Pharma Limited reported trailing-twelve-month revenue of about ₹5.5B (latest available figure, as of Sep 24, 2026).
Does Bliss GVS Pharma Limited pay a dividend?
Bliss GVS Pharma Limited currently shows a dividend yield of about 0.31% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Bliss GVS Pharma Limited (506197)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bliss GVS Pharma Limited it is ₹104.64 per share (as of Sep 24, 2026), against a price of ₹684.20. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Bliss GVS Pharma Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 506197 trades above its calculated fair value: price ₹684.20, fair value ₹104.64, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 506197?
No. The price is what the market pays today (₹684.20); the fair value is what the company's own numbers justify (₹104.64). For Bliss GVS Pharma Limited the two are ₹579.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bliss GVS Pharma Limited worth?
The market values Bliss GVS Pharma Limited at about ₹18.0B (market capitalisation, as of Sep 24, 2026). Per share that is ₹684.20; our models calculate a fair value of ₹104.64 per share.
What do the bullish and bearish scenarios say about 506197?
Our models span a range for Bliss GVS Pharma Limited: cautious scenario ₹59.83, base ₹104.64, optimistic ₹167.11 per share (as of Sep 24, 2026, price ₹684.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 506197?
Bliss GVS Pharma Limited trades at a price-to-earnings ratio of 24.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹104.64 is built from several models across several years. Other multiples: P/B 1.7, P/S 3.3, EV/EBITDA 18.4.
How solid is the balance sheet of Bliss GVS Pharma Limited (506197)?
Balance-sheet figures for Bliss GVS Pharma Limited (as of Sep 24, 2026): return on equity 9.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 506197 from its 52-week high?
Bliss GVS Pharma Limited trades at ₹684.20, about 7% below its 52-week high of ₹737.60 and 436% above the low of ₹127.57 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹104.64 is for.
Which stocks are comparable to Bliss GVS Pharma Limited?
From the same area (Healthcare) we also value Makers Laboratories Limited, COLINZ, Eli Lilly and Company, Johnson & Johnson,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bliss GVS Pharma Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹684.20, calculated fair value ₹104.64 (−85%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 506197 calculated?
We run Bliss GVS Pharma Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹104.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Bliss GVS Pharma Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bliss GVS Pharma Limited (506197)?
The closing price on Oct 1, 2026 was ₹684.20. Our model-based fair value is ₹104.64, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bliss GVS Pharma Limited right now?
The price sits above even our optimistic bull case (₹167.11). The favourable scenario is already priced in. The model range is unusually wide (₹59.83 to ₹167.11). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Bliss GVS Pharma Limited
How large is the market capitalisation of Bliss GVS Pharma Limited (506197)?
The market capitalisation of Bliss GVS Pharma Limited is ₹18.0B (≈ $187M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bliss GVS Pharma Limited (506197)?
The price-to-sales ratio of Bliss GVS Pharma Limited is 2.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bliss GVS Pharma Limited (506197)?
Earnings per share at Bliss GVS Pharma Limited are ₹6.63 (price ÷ EPS = P/E 24.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bliss GVS Pharma Limited (506197)?
The dividend yield of Bliss GVS Pharma Limited is 0.3% (payout 32.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bliss GVS Pharma Limited (506197)?
The net margin of Bliss GVS Pharma Limited is 10.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bliss GVS Pharma Limited (506197)?
The return on equity (ROE) of Bliss GVS Pharma Limited is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bliss GVS Pharma Limited (506197)?
On an EBIT basis the return on assets of Bliss GVS Pharma Limited is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bliss GVS Pharma Limited (506197)?
The operating margin of Bliss GVS Pharma Limited is 15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bliss GVS Pharma Limited (506197)?
Revenue at Bliss GVS Pharma Limited is growing −27.9% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bliss GVS Pharma Limited (506197)?
Earnings per share at Bliss GVS Pharma Limited are growing −35.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Bliss GVS Pharma Limited in the live analysis
One click puts Bliss GVS Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
